Chronic Pain | Disease Landscape & Forecast | G7 | 2021
A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug classes, including nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics. However, opioid analgesics, a cornerstone of chronic pain treatment, are under intense scrutiny from the public, payers, and prescribers, particularly in the United States; such scrutiny provides further opportunities for developers of agents with less risk of abuse or deterrence, agents that are safer and more tolerable, and drugs with novel mechanisms of action (MOAs). The emergence of agents with novel MOAs and the increase in prevalence of key subpopulations (e.g., osteoarthritic [OA] pain, chronic low back pain) will, in part, drive market growth.
QUESTIONS ANSWERED:
- How do interviewed experts perceive the chronic pain therapy market to be changing given the emphasis on the risk of abuse / misuse with opioid analgesics?
- How influential are abuse-deterrent formulations of extended-release / long-acting opioid analgesics on U.S. physicians’ prescribing for severe chronic pain?
- What will be the impact of new analgesics from various drug classes on the highly genericized chronic pain therapy market, most notably Regeneron / Teva / Mitsubishi Tanabe Pharma’s fasinumab, the first-in-class anti-NGF biologic therapy, given its efficacy is counterbalanced with safety risks and given the discontinuation of Pfizer / Eli Lilly’s tanezumab after the completion of a robust Phase III program?
- What are the greatest areas of unmet need in the treatment of chronic pain, and how are the emerging therapies expected to address these unmet needs?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 20 country-specific interviews with thought-leading primary care physicians, pain specialists, neurologists, rheumatologists, and anesthesiologists. Supported by survey data collected for other Clarivate research.
Epidemiology: Prevalence, diagnosed, and drug-treated rates of chronic pain subpopulations by country, specifically chronic low back pain, fibromyalgia, and painful diabetic neuropathy; diagnosed and drug-treated prevalence of rheumatoid arthritis pain, OA pain, and postherpetic neuralgia, by country; total prevalent cases of severe cancer pain, breakthrough cancer pain, neuropathic cancer pain, and metastatic bone pain, by country.
Forecast: Five- and ten-year drug-level sales of key chronic pain therapies through 2030; forecast base-year segmentation by select chronic pain populations.
Emerging Therapies: Phase II: 19 drugs; Phase III / preregistration / registration: 10 drugs.
